Rheumatoid Arthritis, a new study from Decision Resources, Inc., examines the agents in development for rheumatoid arthritis (RA) and details their clinical and commercial outlook. The wide array of therapies in development for RA that are evaluated in this study include new-generation analogues of currently marketed drug classes, members of novel classes, and agents now marketed for other autoimmune diseases that are undergoing trials in RA.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION ) Novel TNF Inhibitors Demonstrate Considerable Promise
Abbott/Cambridge Antibody Technology's adalimumab, a recombinant fully human monoclonal antibody in late-stage development, is drawing great interest from clinical experts who expect it to compete with etanercept (Immunex/American Home Product's Enbrel) and infliximab (Centocor/ Schering- Plough's Remicade). In addition, CDP-870, a novel TNF inhibitor from Celltech/Pharmacia currently in Phase II clinical trials has demonstrated promising therapeutic potential. If these results are corroborated by Phase III trials with subcutaneous administration, the convenience of the drug will be superior to that of etanercept because of its less frequent dosing regimen.
New Anticytokine Agents Generate Competition for Enbrel and Remicade
Following the example of the TNF inhibitors, other new cytokine modulators are being developed. One that has recently received FDA approval is Amgen's anakinra, an IL-1 receptor antagonist indicated for the treatment of moderate to severe RA.
Research and Development Efforts for Second-Generation COX-2 Inhibitors
In 2000, Merck and Pharmacia/Pfizer led the RA symptomatic market with the first two COX-2 inhibitors (Vioxx and Celebrex, respectively). Three second- generation compounds are expected to enter the market during the 2000-2010 study period: Merck's etoricoxib, Pharmacia's valdecoxib, and Novartis's COX- 189. Though these agents may be more selective in targeting COX-2 than currently marketed COX-2 inhibitors, thought leaders interviewed remain unconvinced that these agents promise significant therapeutic advances or significantly greater safety.
Rheumatoid Arthritis offers invaluable strategic intelligence for companies competing in this market. This study is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or email@example.com.
In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org.
In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,